Patients who died with a diagnosis of PCP prior to the institution of mechanical ventilation or who refused mechanical ventilation were also included in this review. All charts were reviewed using standardized case report forms with special emphasis on cause of admission to the ICU, use of mechanical ventilation, medications, and survival. The data collection was performed in the same fashion as in our previous report8 so that trends over time could be compared. Both cohorts are mutually exclusive. Additional drug use data were obtained from computerized pharmacy records.
Only patients in whom the diagnosis of PCP was microbiologically proved were included. Patients who were not actively treated for PCP, either as a result of the patient's wishes or because the diagnosis was not suspected prior to the patient's death, were excluded. Patients who required hospital readmission with an episode of PCP were considered as separate episodes if the hospital discharge date from the initial episode and the subsequent readmission date were more than 30 days apart; readmissions within a 30-day period were considered as a single PCP episode. Acute prophylaxis.14 The proportion of patients with PCP hospitalized, the rate of ARF, the overall mortality, and the PCP-specific mortality remained relatively constant during the study. The annual number of ventilated patients with PCP-related ARF during the study period was 4, 12, 7, and 4 with a mortality of 75%, 83%, 100%, and 100%, respectively.
This contrasts with our experience during the years 1981 to 1987 as shown in Table 2 and Figure 1 .8 During this period, 127 episodes of PCP were diagnosed with a hospital admission rate of 100%; ARF developed in 27 episodes (21%) and most of those (24 patients) were ventilated with a ventilatory mortality of 50%. Thus, between these two periods, there was a striking difference in the case-fatality rate among ventilated patients, which increased from 50% to 89% (p=0.003). A refractory to systemic corticosteroid therapy. The rise in the proportion of patients treated with corticosteroids prior to ICU admission in these intervals was statistically significant (trend test p=0.017).
DISCUSSION
In contrast to previous reports,810"1220 our data suggest that the prognosis of respiratory failure in the context of AIDS-related PCP is extremely poor, if this develops despite maximal therapy, namely antimicrobials and adjunctive corticosteroids.17 It must be emphasized that this may not apply to patients who present late, with established respiratory failure, as this would have developed prior to receiving maximal therapy.
We have been able to account for all diagnosed cases at SPH and we have failed to identify other potential sources for the rise in the case-specific mortality described above. The overall mortality of AIDS-related PCP during the study period remained relatively constant, between 6% and 11% per year. No pattern emerged after careful review of individual ventilated cases with regards to complications of their disease or of the ventilation itself that could account for the worsening in outcome. In particular, the MSOF score did not change significantly during the study. Therefore, the observed changes in mortality cannot be attributed to a selective admission to ICU of more severe cases in latter years.19
The decrease in hospitalizations between the two study periods could be attributed to earlier diagnosis and increased use of oral antimicrobials for the treatment of mild to moderate PCP.18 This would have acted as a conservative bias in the context of our study, as these patients remained under care of our outpatients services and were accounted for with regards to the study outcomes. Against this, we noticed a significant decrease in the frequency of respiratory failure that we can confidently attribute to the increased use of adjunctive corticosteroids on the basis of the available literature. 818 As noted above, the overall mortality of AIDS-re- the worse prognosis in the later phase of our study. Our results show a decreasing frequency but a worsening mortality of ventilated respiratory failure in the context of AIDS-related PCP (Tables 1 and 2 ). Earlier use of corticosteroids was documented during the study period (Figure 1 ). Although our data involve only an ecologic correlation, we believe that adjunctive corticosteroid use is responsible, at least in part, for the observed changes in outcome. A number of prospective studies have now confirmed the beneficial effect of corticosteroids in decreasing the mortality of respiratory failure due to AIDS-related PCP.9'10 Similarly, the effect of oral corticosteroids in preventing the development of respiratory failure among patients with moderately severe AIDS-related PCP has also been documented.'3 Our data suggest that increased use of adjunctive corticosteroids led to a decrease in mortality from ARF due to AIDSrelated PCP in our series during the years 1981 to 1987. Subsequently, with earlier and more liberal use of corticosteroids, before the development of respiratory failure, we have seen a decrease in the frequency of ARF in this disease. Unfortunately, the small number of patients who were admitted to the ICU for ventilatory support, having failed adjunctive corticosteroid therapy, had a very dismal prognosis as shown by a mortality of 100% for the last 2 years of the study.
It must be emphasized that our data show a significant overall decrease in the frequency of ARF secondary to AIDS-related PCP that is attributable to improved management strategies. Despite these encouraging results, we found that the relative(y small proportion of individuals who develop ARF despite maximal therapy have a very high mortality.
We conclude, therefore, that the frequency of respiratory failure developing in the context of AIDS-related PCP has decreased significantly as a result of improved management strategies. However, patients who develop respiratory failure despite maximal medical therapy, including systemic corticosteroids, have a dismal prognosis.
